Mallinckrodt plc
Mallinckrodt plc (MNK) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
mnk · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Mallinckrodt plc (MNK) measures how much investors pay for each dollar of the company's trailing earnings. MNK's current PE ratio of N/A is calculated by dividing its stock price of $0.34 by its TTM earnings per share of -$14.53.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2011 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 7 fiscal years · Front-end computedMinQ1 · 25%5.5x
MedianQ3 · 75%14.6x
Max
At N/A, MNK's current P/E is lower than in 0% of its annual fiscal year readings over the past 7 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Drug Manufacturers - Specialty & Generic · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Mallinckrodt plcYou MNK | $5M | N/A | — | -$14.53 |
 Aptose Biosciences Inc. APTO | $4M | N/A | — | $0.00 |
 BiondVax Pharmaceuticals Ltd. BVXV | $5M | N/A | — | -$0.20 |
 Gamida Cell Ltd. GMDA | $4M | N/A | — | -$0.42 |
 Hillstream BioPharma, Inc. HILS | $4M | N/A | — | -$1.12 |
 Xylo Technologies Ltd. MDGS | $179M | N/A | — | -$380.16 |
 Nabriva Therapeutics plc NBRVF | $0M | N/A | — | -$21.32 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-17.48 | — | |
2024-12-27 FY2024 | 0.00x | $24.26 | — | |
2023-12-29 FY2023 | — | $-0.04 | — | |
2022-12-30 FY2022 | — | $-4.06 | — | |
2021-12-31 FY2021 | — | $-8.54 | — | |
2020-12-31 FY2020 | — | $-11.48 | — | |
2019-12-31 FY2019 | — | $-12.00 | — | |
2018-12-31 FY2018 | — | $-42.94 | — | |
2017-12-31 FY2017 | 0.71x | $21.85 | -73.4% | |
2016-09-30 FY2016 | 2.66x | $5.82 | -51.8% |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Mallinckrodt plc (MNK) measures how much investors pay for each dollar of the company's trailing earnings. MNK's current PE ratio of N/A is calculated by dividing its stock price of $0.34 by its TTM earnings per share of -$14.53.
Frequently asked questions
MNK pe ratio · 6 questionsMNK's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.34 and TTM EPS of -$14.53. Data sourced from Financial Modeling Prep via MNK's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Mallinckrodt plc SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09